Literature DB >> 1119940

Humoral and secretory antibody responses to immunization with low and high dosage split influenza virus vaccine.

F L Ruben, C W Potter, C H Stuart-Harris.   

Abstract

Tri (n-butyl) phosphate (TNBP)-split vaccine containing 6400 CCA units of influenza virus A/Aichi/68 (H3N2) was given intramuscularly to a group of volunteers. The changes in serum haemagglutination-inhibiting (HI) and nasal wash neutralizing antibody were measured, and the results compared with that of volunteers given a TNBP-split vaccine containing 400 CCA of the same virus. More volunteers given the high-dose vaccine developed a fourfold rise in serum HI antibody, and there was a greater increase in geometric mean titre in this group. In addition, more volunteers given the high-dose vaccine developed detectable nasal wash neutralizing and anti-neuraminidase antibodies. Following low-dose vaccine, the production of nasal wash antibody was not related to the serum antibody response. For both groups given vaccine, antibody was detected most frequently in nasal washings with relatively high levels of protein and IgA; the concentration of IgA was also directly related to the protein concentration.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1119940     DOI: 10.1007/bf01320555

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  17 in total

1.  COMPARISONS OF SEROLOGIC AND FEBRILE RESPONSES IN HUMANS TO VACCINATION WITH INFLUENZA A VIRUSES OR THEIR HEMAGGLUTININS.

Authors:  F M DAVENPORT; A V HENNESSY; F M BRANDON; R G WEBSTER; C D BARRETT; G O LEASE
Journal:  J Lab Clin Med       Date:  1964-01

2.  Human febrile response to influenza virus or its ether isolated hemagglutinins.

Authors:  F B Brandon; C D Barrett; A E Hook; G O Lease
Journal:  Proc Soc Exp Biol Med       Date:  1967-07

3.  Evaluation of monovalent influenza vaccines. II. Observations during an influenza a-prime epidemic.

Authors:  G MEIKLEJOHN; C H KEMPE; W G THALMAN; E H LENNETTE
Journal:  Am J Hyg       Date:  1952-01

4.  A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity.

Authors:  F L Ruben; G G Jackson
Journal:  J Infect Dis       Date:  1972-06       Impact factor: 5.226

5.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

6.  Neuraminidase- and hemagglutinin-inhibiting antibodies in serum and nasal secretions of volunteers immunized with attenuated and inactivated influenza B-Eng-13-65 virus vaccines.

Authors:  J C Downie
Journal:  J Immunol       Date:  1970-09       Impact factor: 5.422

7.  Antibody responses in nasal secretions and serum of elderly persons following local or parenteral administration of inactivated influenza virus vaccine.

Authors:  J A Kasel; E B Hume; R V Fulk; Y Togo; M Huber; R B Hornick
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

8.  Reactions to an influenza virus vaccine in infants and children.

Authors:  J J QUILLIGAN; T FRANCIS; E MINUSE
Journal:  Am J Dis Child       Date:  1949-09

9.  Enhanced immunogenicity in mice of a purified, tween-ether-treated influenza vaccine.

Authors:  J D Fenters; H M Yamashiroya; R F Petzold; V K Tolkacz
Journal:  Appl Microbiol       Date:  1970-10

10.  The production of neutralizing activity in serum and nasal secretion following immunization with influenza B virus.

Authors:  J C Downie; C H Stuart-Harris
Journal:  J Hyg (Lond)       Date:  1970-06
View more
  6 in total

1.  A new surface-antigen-adsorbed influenza virus vaccine. II. Studies in a volunteer group.

Authors:  C W Potter; R Jennings; C McLaren; D Edey; C H Stuart-Harris; M Brady
Journal:  J Hyg (Lond)       Date:  1975-12

2.  A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults.

Authors:  Robert L Atmar; Wendy A Keitel; Thomas R Cate; Flor M Munoz; Fred Ruben; Robert B Couch
Journal:  Vaccine       Date:  2007-05-22       Impact factor: 3.641

3.  Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults.

Authors:  Patricia M Flynn; Sharon Nachman; Petronella Muresan; Terence Fenton; Stephen A Spector; Coleen K Cunningham; Robert Pass; Ram Yogev; Sandra Burchett; Barbara Heckman; Anthony Bloom; L Jill Utech; Patricia Anthony; Elizabeth Petzold; Wende Levy; George K Siberry; Ruth Ebiasah; Judi Miller; Edward Handelsman; Adriana Weinberg
Journal:  J Infect Dis       Date:  2012-05-21       Impact factor: 5.226

4.  A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity.

Authors:  A Clark; C W Potter; R Jennings; J P Nicholl; A F Langrick; G C Schild; J M Wood; D A Tyrrell
Journal:  J Hyg (Lond)       Date:  1983-06

5.  High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults.

Authors:  W A Keitel; R B Couch; T R Cate; K R Hess; B Baxter; J M Quarles; R L Atmar; H R Six
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

6.  Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.

Authors:  Patricia Winokur; Hana M El Sahly; Mark J Mulligan; Sharon E Frey; Richard Rupp; Evan J Anderson; Kathryn M Edwards; David I Bernstein; Kenneth Schmader; Lisa A Jackson; Wilbur H Chen; Heather Hill; Abigail Bellamy
Journal:  Vaccine       Date:  2021-01-21       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.